National Institute of Rheumatology, Piestany, Slovakia Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2002
NCT00976300
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

cyclophosphamide (cytoxan) (1 trial)

cyclosporine (sandimmune) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 2)

Nephritis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2